𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Procoagulant activity of mononuclear phagocytes from different anatomical sites in patients with gynecological malignancies

✍ Scribed by N. Semeraro; P. Montemurro; M. Conese; D. Giordano; M. Stella; A. Restaino; G. Cagnazzo; M. Colucci


Publisher
John Wiley and Sons
Year
1990
Tongue
French
Weight
467 KB
Volume
45
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Mononuclear phagocytes exhibit complex interactions with cancer cells and might contribute to fibrin formation associated with malignancy through the production of procoagulant activity (PCA). We have studied the PCA of peritoneal macrophages in 8 patients with advanced (stages III or IV) ovarian cancer and of macrophages from regional lymph nodes in 14 patients with limited (stages I or II) uterine cancer; peritoneal and lymph‐node macrophages from patients with benign gynecological tumors were used as reference cell populations. In all patients, PCA of blood monocytes was also studied. Peritoneal and lymph‐node macrophages obtained from patients with ovarian and uterine cancer, respectively, expressed far higher levels of basal PCA than the corresponding cell populations from patients with benign tumors (p <0.001). PCA of blood mononuclear cells from patients with ovarian, but not with uterine cancer, was significantly higher (p <0.001) than that of control cells. High levels of D‐dimer, a specific product derived from plasmin‐induced degradation of stabilized fibrin, were found in all ascitic fluids and in all plasma samples but one from patients with ovarian cancer. In contrast, all controls and all uterine cancer patients but one had normal plasma D‐dimer. Our findings suggest that local activation of host macrophages for PCA production might contribute to fibrin formation within the tumoral mass. In advanced cancer, blood monocytes may also be activated to produce PCA and thus contribute to activation of intravascular coagulation and, possibly, to thrombo‐embolic complications frequently associated with disseminated malignancy.